Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAFV600D,V600E PLX-Resistant Melanoma and MDR Neuroblastoma, Exhibiting No/Low Toxicity on 3T3/HaCaT Cells
could be used to develop 24 and 48 h treatments for PLX-R MeTRAV cells. Also, all compounds could be developed as new treatment options for both ETO-sensitive and MDR late-stage HR-NB cells, being even more effective than ETO by 1.2, 2.0, and 1.3 times (HTLA 230) and 3.2, 4.7, and 3.2 times (HTLA ER). All compounds have the potential to be developed as adjuvants in already existing anticancer cocktails to treat MCM and/or NB.
Authors
- Maria Grazia Signorello
- Cinzia Domenicotti (ORCID: https://orcid.org/0000-0002-5003-7333)
- Barbara Marengo (ORCID: https://orcid.org/0000-0003-3056-6569)
- Sara Tirendi
- Silvana Alfei (ORCID: https://orcid.org/0000-0002-4630-4371)
- Elaheh Khaledizadeh (ORCID: https://orcid.org/0009-0003-7390-916X)
- Paolo Giordani
- Caterina Reggio
Institutions
- University of Pisa (IT)
- Istituto Giannina Gaslini (IT)
- Azienda Ospedaliera S.Maria (IT)
- University of Genoa (IT)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-03-31
- DOI
- https://doi.org/10.3390/ijms27073170
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00